How to Get Methadone Treatment for Opioid Use Disorder

Methadone treatment for opioid use disorder starts with enrollment at a federally certified opioid treatment program, commonly called an OTP or methadone clinic. Unlike buprenorphine, which a doctor can prescribe from a regular office, methadone for addiction treatment can only be dispensed through these specialized programs. That single requirement shapes almost everything about the process, from finding a clinic to the daily visits most people face early on. The system has real strengths and real frustrations, and understanding both makes navigating it much easier.

Finding a Clinic and Getting In

Your first step is locating an OTP near you. The Substance Abuse and Mental Health Services Administration (SAMHSA) maintains a treatment locator on its website that lets you search by zip code. Your state’s substance use agency or a primary care doctor can also point you to local options. Some clinics have waitlists, so calling ahead to ask about availability and required documents saves time.

Eligibility is straightforward. You need a diagnosis of opioid use disorder, and federal guidelines generally require at least one year of documented opioid dependence, though exceptions exist for people recently released from incarceration, pregnant individuals, and those who have previously been in treatment. When you arrive for intake, expect a medical exam, a urine drug screen, a review of your substance use history, and sometimes blood work. Many programs also screen for mental health conditions, hepatitis C, and HIV. The clinical team uses all of this to build a treatment plan tailored to you.

How Dosing Works in the First Weeks

The early phase of methadone treatment is deliberately cautious. Methadone is long-acting, which is part of what makes it effective, but that same property means it builds up in the body over days. Giving too much too fast, raising the dose too quickly, or missing a dangerous drug interaction can be fatal. Deaths during the induction period are a recognized risk, and the clinical guidelines designed to prevent them reflect that reality.¹

In a typical outpatient program, the starting dose is usually in the range of 20 to 40 mg per day, taken under direct observation at the clinic. Increases happen in small steps every few days based on how you feel, whether withdrawal symptoms are controlled, and whether cravings persist. Some inpatient settings use a more rapid titration approach, starting with a scheduled dose of 30 to 40 mg plus smaller doses available every few hours for breakthrough cravings, up to a capped daily maximum during the first day.² Most outpatient clinics are more conservative, aiming to reach a stable maintenance dose over one to six weeks.

The goal is a dose that keeps withdrawal away for a full 24 hours, reduces cravings, and blocks the euphoric effects of other opioids without causing sedation. For many people this lands somewhere between 60 and 120 mg per day, though individual variation is large. A dose below 60 mg is associated with significantly higher dropout rates, so if you feel your dose is not working, advocating for an increase with your treatment team is reasonable and supported by research.³

Daily Visits, Then Gradually Fewer

For most new patients, the early weeks and months involve going to the clinic every single day to take your dose in front of staff. This is the part of methadone treatment that people find most burdensome, and it is the single biggest difference from buprenorphine, which you can take at home from day one. The rationale is safety and accountability, but the practical impact on jobs, childcare, and daily life is substantial.

As you demonstrate stability, which clinics generally define as negative drug screens, attendance at counseling, and no major behavioral issues, you become eligible for take-home doses. Historically, the federal schedule was rigid: one take-home after 90 days, two after 180 days, and so on, reaching a maximum of roughly a month’s supply only after years of uninterrupted stability. In February 2024, SAMHSA permanently expanded take-home flexibilities that were first introduced during the COVID-19 pandemic, allowing programs to grant take-homes earlier and more generously.⁴ Individual states and clinics still have discretion over whether to adopt the looser rules, so the experience varies depending on where you live.

How Effective Methadone Actually Is

The evidence on methadone’s benefits is unusually strong for an addiction treatment. A large systematic review pooling data from multiple cohort studies found that all-cause death rates were roughly three times higher outside of methadone treatment than while enrolled, and overdose death rates were nearly five times higher outside of treatment.⁵ A Canadian population-based study of people with criminal convictions found that accidental overdose deaths were about three times lower during medicated periods, and deaths from infectious diseases were five times lower.⁶

These survival benefits hold across different populations and treatment settings. Even in a low-threshold program in Vancouver, where entry requirements were minimal and many participants had HIV, enrollment in methadone maintenance was associated with significantly improved survival after adjusting for age and other health factors.⁷ The reduction in mortality is not just about overdose prevention. Methadone treatment also reduces injection drug use, needle sharing, and engagement in behaviors that spread bloodborne infections.

Methadone Compared to Buprenorphine

The main alternative medication for opioid use disorder is buprenorphine, sold under brand names like Suboxone. Both work, but they differ in ways that matter for individual patients. Methadone generally keeps more people in treatment over time. A large Canadian study found that people started on buprenorphine/naloxone were significantly more likely to discontinue than those started on methadone, with about 89% of buprenorphine patients discontinuing within two years compared to roughly 82% of methadone patients.⁸ A randomized trial found a 74% completion rate for methadone versus 46% for buprenorphine, with the gap narrowing when higher doses of both medications were used.³

On the other hand, among patients who stayed in treatment, buprenorphine was associated with fewer positive opioid urine tests, suggesting it may be better at suppressing continued illicit use for those who tolerate it.³ Buprenorphine also has a major practical advantage: it can be prescribed by any qualified provider and taken at home, eliminating the daily clinic visits. For someone with a stable job, reliable transportation, and moderate rather than severe opioid dependence, buprenorphine may be the better fit. For someone with a long history of heavy use, prior buprenorphine failures, or a need for the structure a clinic provides, methadone tends to be more reliable.

Safety Concerns Worth Knowing About

Methadone is a safe medication at therapeutic doses under medical supervision, but it carries risks that your treatment team should monitor. The most discussed is its effect on heart rhythm. Methadone can prolong a specific interval on an electrocardiogram called the QTc, which at extreme values raises the risk of a dangerous irregular heartbeat.⁹ This has been reported even at standard therapeutic doses, though clinically significant arrhythmias remain uncommon.¹⁰ Many clinics obtain a baseline EKG and repeat it after dose increases or if symptoms like dizziness or fainting occur.

Drug interactions are the other major safety issue. Benzodiazepines like diazepam are particularly dangerous in combination with methadone because they can slow breathing to lethal levels. Research has shown that diazepam directly inhibits methadone’s metabolism, causing it to accumulate to higher concentrations in the body.¹¹ Alcohol poses a similar respiratory risk. Certain antibiotics, antifungals, and HIV medications can also raise or lower methadone levels unpredictably. Always tell your treatment team about every medication and supplement you take, including over-the-counter products.

Methadone During Pregnancy

If you are pregnant and dependent on opioids, methadone has been the recommended standard of care for decades. Abruptly stopping opioids during pregnancy is dangerous and can cause miscarriage or preterm labor, so medication-assisted treatment is the safer path. A landmark double-blind trial published in the New England Journal of Medicine confirmed both the safety and usefulness of methadone during pregnancy, while also finding that buprenorphine produced a milder neonatal withdrawal syndrome in newborns.¹²

A common worry among pregnant patients is that a higher dose will cause a worse withdrawal syndrome in the baby. A systematic review and meta-analysis addressed this directly and found that the severity of neonatal abstinence syndrome did not appear to differ based on whether the mother was on a high or low methadone dose.¹³ In other words, reducing your dose below what keeps you stable does not protect the baby and does put you at greater risk of relapse. The right dose is whatever dose keeps you well.

Geographic and Financial Barriers

The biggest obstacle to methadone treatment for many people is simply getting to a clinic. Nationwide, about 18% of the U.S. population lacks geographic access to a methadone clinic, and modeling estimates suggest that roughly 78,000 additional people would seek treatment if a clinic were within reach.¹⁴ Rural areas are hit hardest. Even under optimistic assumptions about how far people will travel, few areas have what researchers consider reasonable geographic access to methadone providers.¹⁵

Even where clinics exist, not everyone goes to the closest one. A study of client behavior found that nearly half of treatment episodes involved “bypassing,” meaning the patient traveled past the nearest facility to attend a different one. About a fifth of all episodes involved at least five extra minutes of commuting. Bypass rates varied across racial and ethnic groups, with Black clients showing higher rates than white clients and sometimes choosing clinics with longer wait times.¹⁶ The reasons likely include perceived quality differences, comfort, and avoidance of stigma at certain locations.

Cost varies widely depending on insurance. Medicaid covers methadone treatment in most states and is the largest payer for OTP services. Medicare added coverage more recently. Private insurance plans have been less consistent, and some offer little or no access to methadone.¹⁷ For uninsured patients, many clinics offer a sliding-scale fee, often in the range of $50 to $125 per week for daily dosing and counseling. Some states fund slots for uninsured patients through block grants. Calling ahead and asking about payment options before your first visit prevents surprises.

Stigma as a Real Barrier

The stigma around methadone treatment is not just a vague cultural discomfort. It measurably interferes with care. A recent observational study found that nearly two-thirds of patients on methadone or buprenorphine reported moderate to high levels of self-stigma. Nearly half had experienced stigma from a healthcare professional because of their opioid use or treatment, and roughly a third had been refused care by a provider because of it. About a quarter reported delaying medical care out of fear of being stigmatized.¹⁸ This is not a minor annoyance. When people avoid medical care because they are on methadone, treatable conditions go unmanaged. If you encounter stigmatizing treatment from a healthcare provider, you are not imagining it, and it is worth reporting to clinic staff or a patient advocate.

Mental Health Care Alongside Methadone

Depression, anxiety, PTSD, and other psychiatric conditions are extremely common among people entering methadone treatment. Most OTPs offer or refer to mental health services, and engaging in that care matters for long-term stability. The reality is that follow-through is often poor. One study of patients referred to parallel psychiatric care found that while about 80% started treatment, the average length of engagement was only about four months, patients attended only a third of their scheduled appointments, and 84% did not complete a full year. More than half left psychiatric care while still receiving substance use treatment. Patients with concurrent cocaine or alcohol problems had the worst retention.

The modest improvements in psychological distress that researchers observed in those who did engage suggest that psychiatric treatment helps, but the system needs to meet patients where they are. Integrated models that embed mental health services directly in the OTP rather than sending patients to a separate clinic tend to produce better engagement. If your program offers on-site counseling or psychiatric services, taking advantage of that convenience is worth the effort.

Starting Treatment During or After Incarceration

People leaving jail or prison face an extraordinarily high overdose risk in the days and weeks after release because their tolerance has dropped. Starting methadone or buprenorphine while still incarcerated dramatically changes those odds. A study of New York City jail releases found that in-jail medication treatment was associated with an 80% reduction in overdose mortality during the first month after release.¹⁹ A statewide program in Rhode Island that implemented medications for addiction treatment across the correctional system saw a roughly 60% reduction in post-incarceration overdose deaths after just one year.²⁰

Not all jails and prisons offer methadone, and many that do restrict it to people who were already enrolled before incarceration. This is changing, but slowly. If you or a family member is incarcerated and has opioid use disorder, asking about medication treatment options as early in the stay as possible gives the best chance of a smooth transition to community-based care after release.

What Tapering Off Looks Like

Some people stay on methadone for years or indefinitely, and the evidence supports that as a safe, effective choice. Others want to taper off eventually. The research on tapering is clear on one point: going slow matters more than almost anything else. A population-based study found that only about 13% of methadone treatment episodes ended in what researchers defined as a sustained successful taper, meaning the person reached a minimal dose and did not re-enter treatment, get hospitalized for opioid-related causes, or die within 18 months. Tapers lasting more than a year had nearly seven times the odds of sustained success compared to tapers completed in under 12 weeks.²¹

The rate of dose reduction also matters. Research comparing different tapering speeds found that reducing by less than 5 mg per week was better than faster reductions, and for people with a low relapse risk before tapering, an even gentler pace of less than 2.5 mg per week was optimal.²² A gradual, stepped schedule where the dose decreases in only about a quarter to half of the weeks during the taper, rather than every single week, provided the highest odds of lasting success.²¹ If your provider proposes a rapid taper, the data justify pushing back and asking for more time.

Mobile Clinics and Expanding Access

Because so much of the access problem comes down to geography, mobile methadone units are one of the more promising innovations in the field. These are essentially clinics on wheels, licensed OTPs that travel to underserved areas on a regular schedule. Reviews of mobile programs have found retention rates that often match or exceed those of fixed-site clinics, along with reductions in HIV and hepatitis C transmission in the populations they serve.²³ They are particularly valuable for reaching people who are homeless, living in rural areas, or otherwise unable to get to a brick-and-mortar facility.

Simulation research suggests that mobile units could meaningfully increase methadone use in underserved rural locations, but the benefit depends heavily on where the units are deployed. Careful planning of routes and stops is needed to avoid placing mobile capacity in areas that are already well served.²⁴ SAMHSA has been approving more mobile units in recent years, and asking your state’s substance use authority whether any mobile programs operate in your area is worth a call if you live far from a fixed clinic.